FIRECREST Customer Support

New qualitative research from ICON explores patient experiences in advanced/metastatic hepatocellular carcinoma, identifying fatigue, weight loss, weakness, appetite reduction, and sleep disturbance as the most frequent ...

Come along to Rüdiger Kaspera's Learning Lab at ASCPT, where he’ll dive into science and risk based strategies for designing oligonucleotide First‑in‑Human studies - covering toxicity, study design, PK/PD, population se...

Ultra rare disease progress does not happen by accident. Register for our webinar to hear how patient leaders are accelerating therapies and redefining what is possible through practical, repeatable expert‑proven model...

Patient leadership is a catalyst for innovation in ultra rare diseases. Hear directly from leaders who are challenging regulatory norms, driving first in human treatments and bringing hope and treatments to families fast...

Rare Disease Day takes place on 28 February. ICON is committed to raising awareness for the 300 million people impacted globally. Over the past 5 years, ICON has participated in 810+ rare disease clinical studies, enro...

Heading to ADPD 2026? Visit ICON at booth \#29 to discuss how our early development and neuroscience teams support more informed decision making in neurodegenerative research. With in house early phase capabilities and...

Non-invasive testing could transform the management of metabolic liver disease and help shape the future of MASH clinical development. This article in SelectScience® Science explores the evolving NIT landscape, emerging...

Join us to explore the latest best practices in global flow cytometry QC and harmonisation. During this webinar hosted by Bioanalysis Zone ICON’s flow cytometry specialists will discuss: - Industry best practices for h...

In recognition of Rare Disease Day, join ICON’s Centre for Rare Diseases for an inspiring panel at our upcoming webinar on 3 March at 11 am EST. Hear directly from parent and patient leaders whose advocacy is driving f...

2025 signalled a reset for global biotech, with capital discipline, shifting partnership models and sharper execution shaping the year. Asia’s expanding R&D footprint further underlined the sector’s geographic diversific...

The EU Joint Clinical Assessment is already influencing how oncology therapies are developed and assessed across Europe. In this article, Dr. Liz O’Brien of ICON explains how #JCA is driving earlier evidence generation, ...

Formulations in early clinical development require a delicate balance of flexibility, simplicity, and scientific rigor. In first‑in‑human trials, dose ranges can vary by 10–100 fold increase between the starting dose a...